If you weigh 180 pounds, a 10% reduction is 18 pounds
This was patented by Novo Nordisk in 1996 and the first paper on it was published in 2000 (Knudsen, Nielsen, Huusfeldt)
A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at 13 weeks for adults with overweight or obesity, according to findings from the VENTURE trial published in Obesity
However, individual tolerability and safety to GLP-1RA may vary due to differences in molecular structures (77)
Zhong et al., 2021), the first oral GLP-1RA in the world, which provides effective glycemic control in type 2 diabetes when combined with diet and exercise intervention, bringing great convenience to patients ( 5 Conclusion In conclusion, semaglutide can significantly reduce weight and BMI for obese or overweight patients without diabetes and has a positive effect on heart-related risk factors such as waist circumference, blood pressure, CRP, and lipid profiles with acceptable safety and high compliance, which can effectively improve obese patients health and quality of life
This framework is evidence-informed rather than a validated GLP-1specific guideline
